Microbot Medical Announces New Webinar Series to Engage Stakeholders with Experts in the Healthcare Space
November 15 2022 - 7:00AM
Microbot Medical Inc. (Nasdaq: MBOT), announced that it will be
hosting a monthly educational webinar series, the
Access-Ability Live by MBOT, to
focus on key issues impacting the future of the endovascular space,
including robotics and other medical devices that will improve
patient outcomes, and the place that the LIBERTY® Robotic System is
expected to play in it. Each month, the Company plans to partner
with industry leaders, such as physicians, hospital administrators,
entrepreneurs, technicians and financial experts for a live
discussion and Q&A session to address top-of-mind healthcare
related topics.
The initial webinar will be held on November 16,
2022, at 1:00 pm ET, and hosted by the Company’s Chief Medical
Officer, Dr. Eyal Morag. Dr. Morag’s guest speaker will be Dr.
Sebastian Flacke, a global leader in the endovascular space and
Chief of Interventional Radiology and Director of non-invasive
Cardiovascular Imaging at Lahey Hospital & Medical Center. Dr.
Flacke is expected to address the current landscape for
endovascular procedures, and how it has changed over the past and
the emerging technologies being developed today that can
potentially and significantly change how these procedures are going
to be performed in the near future. Dr. Flacke will also share his
recent hands-on experience with the LIBERTY Robotic System and the
future impact that he believes it will have on his practice once
the system is cleared for commercialization in the U.S.
“Over the last couple of months, we have noticed
increased interest in our LIBERTY® Robotic System technology by
multiple stakeholders, ranging from physicians, investors,
strategic partners, and others, which coincides with our continued
efforts towards the regulatory and commercialization phases,”
commented Harel Gadot, Chairman, CEO and President. “To address
this growing interest and ensure we are engaging with our key
stakeholders, it’s critical they hear first-hand from industry
experts about the growing unmet needs in the endovascular space,
and how the LIBERTY Robotic System has the potential to resolve
many of the challenges being experienced today. Our decision to
launch the Access-Ability Live by
MBOT webinar series is meant to establish an online
community of industry leaders who are interested in robotics to
come together and share their experience.”
To participate on the webinar, please register
in advance at:
https://us06web.zoom.us/webinar/register/WN_BslG0qO6QJem2Ew_gPSCuw.
After registering, participants will receive a confirmation email
containing information about joining the webinar.
About Microbot
Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, focused primarily on
both natural and artificial lumens within the human body.
Microbot’s current proprietary technological platforms provide the
foundation for the development of a Multi Generation Pipeline
Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel
Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of
improving clinical outcomes for patients and increasing
accessibility through the use of micro-robotic technologies.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions,
risks inherent in the development and/or commercialization of
potential products, including LIBERTY and the One &
Done™ technologies, the outcome of its studies to evaluate
LIBERTY, the One & Done™ technologies and other existing
and future technologies, any failure or inability to recruit
physicians and clinicians to serve as primary investigators to
conduct regulatory studies which could adversely affect or delay
such studies, uncertainty in the results of pre-clinical and
clinical trials or regulatory pathways and regulatory approvals,
uncertainty resulting from the COVID-19 pandemic, need and ability
to obtain future capital, and maintenance of intellectual property
rights. Additional information on risks facing Microbot Medical can
be found under the heading “Risk Factors” in Microbot Medical’s
periodic reports filed with the Securities and Exchange Commission
(SEC), which are available on the SEC’s web site at www.sec.gov.
Microbot Medical disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Contact:
Michael PolyviouEVC Groupmpolyviou@evcgroup.com732-933-2754
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2023 to Apr 2024